By enhancing FGF21 expression, MB109 (a recombinant derivative of human BMP9) effectively reduces obesity-induced liver pathologies, including inhibiting lipid accumulation in the liver and significantly decreasing serum levels of alanine aminotransferase (ALT), aspartate transaminase (AST), and total cholesterol. The gene discussed is GDF2; the disease is Obesity.